Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient with Richter Transformation: A Case Report and Review of the Literature.

Thomas PariggerStephan DrothlerChristian ScherhäuflFranz Josef GassnerMaria SchubertMarkus SteinerJan Philip HöpnerAlexandra HödlmoserLena SchultheisAryunni Abu BakarDaniel NeureiterLisa PleyerAlexander EgleRichard GreilRoland GeisbergerNadja Zaborsky

Published in: Acta haematologica (2024)

Thus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
newly diagnosed
cell proliferation
ejection fraction
chronic kidney disease
tyrosine kinase
prognostic factors
transcription factor
case report
mesenchymal stem cells
smoking cessation